Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012
18 mars 2013 15h23 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 18, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the fiscal year ended December 31, 2012. The net loss for 2012's twelve month...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
04 mars 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
Hemispherx Biopharma Receives Complete Response Letter From FDA on Ampligen(R) New Drug Application for Chronic Fatigue Syndrome
04 févr. 2013 19h35 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Feb. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received a Complete Response Letter from the US Food and...
FDA Advisory Committee Makes Recommendations on Ampligen (R) for Chronic Fatigue Syndrome
21 déc. 2012 14h57 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Dec. 21, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended September 30, 2012
02 nov. 2012 15h11 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 2, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended September 30, 2012. The net comprehensive loss for the period...
Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
22 oct. 2012 08h49 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
Hemispherx Biopharma Files for Treatment Expansion in Argentina for Alferon N Injection(R) for Hepatitis C
01 oct. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 1, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx") announced that the Company has filed with ANMAT (Administracion Nacional de...
Hemispherx Biopharma Announces FDA Advisory Committee Will Review Ampligen(R) for Chronic Fatigue Syndrome
24 sept. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced that the U.S. Food and Drug Administration ("FDA") has...
Hemispherx Biopharma Reports on Annual Stockholder Meeting
19 sept. 2012 15h44 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 19, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that it held its 2012 Annual Meeting of Stockholders on September 18, 2012. Final voting results will be...
Hemispherx Biopharma to Present at the Rodman and Renshaw 14th Annual Healthcare Conference
06 sept. 2012 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 14th Annual...